Spotlight on Orthopedics
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Biosimilars
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the utilization of biosimilars in rheumatoid arthritis.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the utilization of biosimilars in rheumatoid arthritis.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Orthopedics Presentations
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – RA
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Utilize appropriate biomarker testing to identify patients with early inflammatory disease.
- Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of rheumatoid arthritis (RA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Utilize appropriate biomarker testing to identify patients with early inflammatory disease.
- Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of rheumatoid arthritis (RA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – Biosimilars
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the utilization of biosimilars in rheumatoid arthritis.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to communicate with patients regarding biosimilars to identify patients who may prefer a biosimilar over a reference biologic.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Jeffrey Kaine will discuss the utilization of biosimilars in rheumatoid arthritis.
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – PSA
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
- Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.
Activity Description
In this CME podcast, Dr. John Tesser and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of psoriatic arthritis (PsA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
- Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.
Activity Description
In this CME podcast, Dr. John Tesser and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of psoriatic arthritis (PsA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – axSpA
StartActivity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Leonard Calabrese will discuss the diagnosis and management of axial spondyloarthritis (axSpA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
MOC point(s)
Expires: October 27, 2020
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).
Learning Objective
Upon successful completion of this activity, participants should be better able to evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
Activity Description
In this CME podcast, Dr. Grace Wright and Dr. Leonard Calabrese will discuss the diagnosis and management of axial spondyloarthritis (axSpA).
Faculty
Activity Chair
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Faculty
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are
required to disclose to the activity audience the relevant financial
relationships of the planners, faculty, reviewers, and staff
involved in the development of CME content. An individual has a relevant
financial relationship if he or she has a financial relationship in any
amount occurring in the past 12 months with a commercial interest whose
products or services are discussed in the CME activity content over which the
individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of
Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Successful
completion of this CME activity enables the participant to earn up to 0.25
MOC points in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants who opt-in will earn
MOC points equivalent to the amount of CME credits claimed for the activity.
It is the CME activity provider’s responsibility to submit participant
completion information to ACCME for the purpose of granting ABIM MOC
points.
This enduring material is approved for 1 year from the date of original
release, October 28, 2019 to October 27, 2020.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road,
Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax:
856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical
Education. All rights reserved. No part of this publication may be reproduced
without written permission from the publisher.
The material presented at or in any of Vindico Medical Education continuing
medical education activities does not necessarily reflect the views and
opinions of Vindico Medical Education. Neither Vindico Medical Education nor
the faculty endorse or recommend any techniques, commercial products, or
manufacturers. The faculty/authors may discuss the use of materials and/or
products that have not yet been approved by the US Food and Drug
Administration. All readers and continuing education participants should
verify all information before treating patients or utilizing any
product.
CME Questions?
Contact us at CME@VindicoCME.com
Addressing Real-World Practice Gaps in the Management of RA
StartActivity Details
Expires: September 29, 2020
Accredited By
Advancing Knowledge in Healthcare (AKH, Inc.)
Target Audience
This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
- Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
- Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
- Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA
Activity Description
Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?
Statement of Educational Need
Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.
Faculty
Arthritis Research UK Professor, Rheumatology
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases
R. J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Professor, Head of Rheumatology and Translational Research
Division of Infection and Immunity
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)
Cardiff University School of Medicine
Cardiff, UK
Conflict of Interest Policy/ Disclosure Statement
It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
- Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
- Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
- Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
- Sharon Powell has no affiliations with commercial interests to disclose.
AKH Staff and Planners
- Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
- Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA)
accepts AMA PRA Category 1 Credit™ from organizations
accredited by ACCME.
Instructions for Receiving Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test and evaluation.
Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI),
a full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions about the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.
Activity Details
Expires: September 29, 2020
Accredited By
Advancing Knowledge in Healthcare (AKH, Inc.)
Target Audience
This educational activity is designed for rheumatology healthcare professionals who manage patients with rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
- Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
- Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
- Incorporate patient preferences, shared decision making, and patient education into the management plan for patients with RA
Activity Description
Is a JAK inhibitor an oral IL-6 inhibitor? Is there a typical “TNFi-patient” versus an “IL-6i patient?” How do IL-6 inhibitors affect mood if they don’t cross the blood-brain barrier? We’ve sourced some of the most pressing questions about rheumatoid arthritis (RA) from leaders around the world, and then brought them together to discuss them. We’ve also asked a patient with RA about her experience with the disease and its treatment. In this activity, we put their expert opinion against a patient’s true story. Will they match up?
Statement of Educational Need
Suboptimal management of patients with rheumatoid arthritis (RA) results in disability, inability to work, and substantial direct and indirect cost burden. Outcomes data from previous RA programs and from the literature indicate that despite the fact that effective use of disease-modifying antirheumatic drugs (DMARDs) greatly reduces the potential for joint destruction, systemic immune effects, and disability, rheumatology providers are not effectively utilizing DMARDs, switching drugs when appropriate, utilizing appropriate monitoring tools, using effective SDM strategies to optimize care, nor effectively selecting newer agents when making treatment decisions.
Faculty
Arthritis Research UK Professor, Rheumatology
Director, NIHR Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds Institute of Rheumatic and Musculoskeletal Medicine
University of Leeds
Leeds, UK
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Vice Chairman, Department of Rheumatic and Immunological Diseases
R. J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Professor, Head of Rheumatology and Translational Research
Division of Infection and Immunity
Director, Arthritis Research UK CREATE Centre and Welsh Arthritis Research Network (WARN)
Cardiff University School of Medicine
Cardiff, UK
Conflict of Interest Policy/ Disclosure Statement
It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Leonard H. Calabrese, DO, has affiliations with AbbVie, Amgen, BMS, Crescendo, Genentech, Gilead, GSK, Horizon, Janssen, Lily, Pfizer, Sanofi-Genzyme, UCB (Consultant); AbbVie, BMS, Genentech, Horizon, Janssen, Lily, Sanofi (Speakers Bureau).
- Ernest Choy, MD, FRCP, has affiliations with Bio-Cancer, Biogen, Novartis, Novimmune, Pfizer, Roche, Sanofi, UCB (Contracted Research); AbbVie, Amgen, Biogen, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm, Sanofi (Consultant); Amgen, BMS, Boehringer Ingelheim, Chugai Pharma, Eli Lilly, Hospira, MSD, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, UCB (Speakers Bureau).
- Paul Emery, MA, MD, FRCP, FMedSci, MARC (Chair), has affiliations with AbbVie, Amgen, BMS, Gilead, Lilly, MSD, Novartis, Pfizer, Samsung, Sanofi (Consultant).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
- Lobna Eldasher, PharmD, has no affiliations with commercial interests to disclose.
- Sharon Powell has no affiliations with commercial interests to disclose.
AKH Staff and Planners
- Dorothy Caputo, MA, BSN, RN, Director of Accreditation, Planner, has no affiliations with commercial interests to disclose.
- Patricia Brignoni, AKH, Director of Operations, has disclosed no relevant financial relationships.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA)
accepts AMA PRA Category 1 Credit™ from organizations
accredited by ACCME.
Instructions for Receiving Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print immediately. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity post-test and evaluation.
Physicians and PAs who successfully complete the post-test and evaluation will receive CME/CE credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI),
a full-service medical education company. The winner will be selected via
automated random drawing on a monthly basis from among all eligible entries
and notified through the contact information provided. In accordance with our
privacy policy, we do not share your information with any third parties. By
entering the sweepstakes, you grant RMEI permission to use your e-mail
address to reach you for notification and prize fulfillment. Only individuals
who complete the evaluation forms and provide contact information will be
eligible to win. Open to those who have a US postal address and who are 18
years or older. Only one prize per person and per household will be awarded.
The prize will be a $100 Amazon gift card.
Statement of Commercial Support
This educational activity is supported by an independent medical educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclaimer Statement
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information for Questions about the Activity
Please contact Nicole Neely at nneely@rmei.com for questions regarding this activity.
Ensuring Early Diagnosis and Targeting Treatment to Remission in Patients with Rheumatoid Arthritis: Recommendations for Primary Care Clinicians
StartActivity Details
Expires: June 21, 2020
Provided By
Target Audience
This educational activity has been designed for primary care clinicians, physician assistants, and nurse practitioners involved in the management of patients with rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement screening to improve early diagnosis of RA
- Apply a treat-to-target approach that is consistent with current guideline recommendations for RA management
- Describe the mechanisms of action of approved targeted therapies for the treatment of RA
- Utilize strategies for early identification of important comorbidities and their management in patients with RA
Activity Description
Simulation Activity
Statement of Educational Need
RA imposes a significant healthcare burden in the US and many affected individuals continue to report poor quality of life despite ongoing treatment. Although numerous therapies are currently available, deficits in knowledge regarding their mechanisms of action and appropriate use, as well as inadequate compliance with published guidelines, remain persistent among clinicians. Additionally, many clinicians report a lack of awareness regarding the increase in risk for certain comorbidities and how to approach their management in patients with RA. Collectively, these observations indicate an important need for additional education regarding the early diagnosis of RA, the efficacy and safety of targeted therapies for treatment, and the implementation of a treat-to-target approach to disease management that takes into consideration the presence of comorbid conditions. With this in mind, this program has been developed to aid primary care clinicians, who are often at the frontline of care for individuals with RA, in acquiring the knowledge and skills required to improve the health outcomes of these patients.
Faculty
Clinical Professor of Medicine
Department of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Roy Fleischmann, MD
Advisory Boards: AbbVie, Eli Lilly & Company,
Pfizer
Contracted Research: AbbVie, Eli Lilly & Company,
Gilead, Pfizer
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2019 through June 21, 2020, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions about the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Activity Details
Expires: June 21, 2020
Provided By
Target Audience
This educational activity has been designed for primary care clinicians, physician assistants, and nurse practitioners involved in the management of patients with rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement screening to improve early diagnosis of RA
- Apply a treat-to-target approach that is consistent with current guideline recommendations for RA management
- Describe the mechanisms of action of approved targeted therapies for the treatment of RA
- Utilize strategies for early identification of important comorbidities and their management in patients with RA
Activity Description
Simulation Activity
Statement of Educational Need
RA imposes a significant healthcare burden in the US and many affected individuals continue to report poor quality of life despite ongoing treatment. Although numerous therapies are currently available, deficits in knowledge regarding their mechanisms of action and appropriate use, as well as inadequate compliance with published guidelines, remain persistent among clinicians. Additionally, many clinicians report a lack of awareness regarding the increase in risk for certain comorbidities and how to approach their management in patients with RA. Collectively, these observations indicate an important need for additional education regarding the early diagnosis of RA, the efficacy and safety of targeted therapies for treatment, and the implementation of a treat-to-target approach to disease management that takes into consideration the presence of comorbid conditions. With this in mind, this program has been developed to aid primary care clinicians, who are often at the frontline of care for individuals with RA, in acquiring the knowledge and skills required to improve the health outcomes of these patients.
Faculty
Clinical Professor of Medicine
Department of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas
Conflict of Interest Policy/Disclosure Statement
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Roy Fleischmann, MD
Advisory Boards: AbbVie, Eli Lilly & Company,
Pfizer
Contracted Research: AbbVie, Eli Lilly & Company,
Gilead, Pfizer
Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2019 through June 21, 2020, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Contact Information for Questions about the Activity
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
StartActivity Details
0.75 CNE Contact Hour
Expires: February 24, 2020
Co-provided By
Target Audience
Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.
Learning Objectives
- Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
- Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
- Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS
Activity Description
This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.
Statement of Educational Need
Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.
Agenda
- Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
- Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
- Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients
Faculty
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin
Disclosures of Conflict of Interest
All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.
Alvin F. Wells, MD, PhD
Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
Statement of Commercial Support
This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.
Activity Details
0.75 CNE Contact Hour
Expires: February 24, 2020
Co-provided By
Target Audience
Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.
Learning Objectives
- Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
- Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
- Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS
Activity Description
This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.
Statement of Educational Need
Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.
Agenda
- Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
- Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
- Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients
Faculty
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin
Disclosures of Conflict of Interest
All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.
Alvin F. Wells, MD, PhD
Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
- Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
- 60 minutes of participation = 1 CNE contact hour
Statement of Commercial Support
This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information for Questions About the Activity
For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.